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INTRODUCTION
Parkinson’s disease (PD) is a progressive neurological con-
dition which is characterized and diagnosed by the presence
of classical motor symptoms, such as tremor, rigidity, bradyki-
nesia and gait disturbance. Patients with PD may also expe-
rience many complaints beyond motor symptoms, which are
referred to as non-motor symptoms (NMS). Ever since James
Parkinson first described the disease, various disturbances not
associated with motor symptoms have been noted (1). 
The NMS of PD is very diverse. These include neuropsy-
chiatric symptoms, sleep disturbance, dysautonomia and sen-
sory symptoms, and have a great impact on the quality of life
for PD patients (2). These symptoms may be ascribed to exten-
sive pathology within the brain. This pathology includes dam-
age to the brainstem, as well as to the cerebral cortex, as sho-
wn by Braak et al. (3). These symptoms are also generally
acknowledged to be poorly responsive to dopaminergic
treatment (4). Although these contribute to disability and
impaired quality of life, NMS are often poorly recognized and
recognition of these symptoms is essential for the optimal
care of patients with PD (5).
In this study, we attempted to elucidate the clinical spec-
trum and prevalence of non-motor symptoms during off peri-
ods (NMOS) distinct from fluctuation of NMS (NMSF), whi-
ch was previously reported (6-8), occurring during not only
off but on or biphasic periods. This study investigating only
NMOS has several clinical implications. First, most fluctu-
ating NMS occurs during off periods. It is plausible that, gi-
ven that motor fluctuation has different clinical features; dysk-
inesia or cranio-cervical dystonia during on state and various
parkinsonian features during off state, the clinical spectrum
of NMS during off state will be different from that occurring
on state. Thus, the pattern of NMOS might be different from
that of NMSF. Second, therapeutically, we can speculate that
NMOS is easier to manage with several strategies shortening
the off period than NMS occurring during on period like mo-
tor symptoms where parkinsonian features occurring during
off period are much easier to manage than dyskinesia occur-
ring during on state. Previous reports indicated that some of
NMOS improved by adding or rearranging dopaminergic reg-
imen (6, 9), but little has been known about responsiveness
of NMS occurring during ‘on’ state, implying the impor-
tance of early recognition of NMOS in PD. 
We also compared the two groups (M-off and NM-off) and
investigated the association of NMOS with regard to other
parkinsonian characteristics, such as the sex, age, age of dis-
ease onset, symptom of onset (tremor vs. akinetic-rigid domi-
nant), duration of disease and levodopa administration, dose
of levodopa, interval between onset of parkinsonian symp-
toms and off symptoms, off periods, severity of motor symp-
toms, and modified Hoehn and Yahr stage.
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Non-Motor Off Symptoms in Parkinson's Disease
The aim of this study is to elucidate the clinical spectrum and frequency of non-motor
symptoms during off periods (NMOS) in Parkinson’s disease (PD) patients with motor
fluctuation. We compared clinical characteristics between PD patients with motor
symptoms only (M-off) and those with both motor and non-motor symptoms (NM-
off) during off periods. The association of NMOS with parkinsonian clinical charac-
teristics was also investigated. Sixty-seven consecutive PD patients of both M-off
and NM-off groups were included in this study. We reviewed medical records, inter-
viewed the patients, and administered a structured questionnaire. NMOS is classi-
fied into three categories: autonomic, neuropsychiatric and sensory. The frequency
of NMOS and their individual manifestations were assessed. Of 67 patients with off
symptoms, 20 were M-off group and 47 NM-off group. Among NMOS, diffuse pain
was the most common manifestation, followed by anxiety and sweating. There were
no significant differences between M-off and NM-off groups with regard to age, dura-
tion of disease and treatment, interval between onset of parkinsonian symptoms and
off symptoms and off periods. Patients taking higher dosage of levodopa had fewer
NMOS. NMOS is frequent in PD. Comprehensive recognition of NMOS can avoid
unnecessary tests and is important for optimal treatment in PD.
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Subjects
We evaluated 67 consecutive out-patients (23 males and
44 females) from Parkinson’s disease Center in Dong-A Uni-
versity Medical Center. They were diagnosed as clinically pro-
bable PD under the criteria of Gelb and colleagues (10). All
patients had been treated with dopaminergic therapy includ-
ing levodopa and showed motor fluctuation, including ‘wear-
ing-off’. Patients with clinically overt dementia or severe de-
pression were excluded in the study. We divided the patients
into two groups; the patients who had only motor symptoms
(M-off group) and the patients with non-motor symptoms
(NM-off group) during motor off periods. All patients in this
study had provided written informed consent. The study was
approved by institutional review boards of Dong-A University.
Methods
This study involved taking a careful history about PD, in-
cluding the duration of symptoms and treatment, onset and
character of motor complication, and medication. All the pa-
tients were prospectively investigated and interviewed during
on phase. Motor performance was evaluated on symptom tri-
ad using the Unified Parkinson’s Disease Rating Scale (20,
23, 26 of part III) and Hoehn and Yahr stage (11, 12).
All the patients were interviewed in a standard motor state
with a structured questionnaire, which were categorized as 4
sensory, 16 autonomic and 8 cognitive/psychiatric symptoms
(Table 1). These symptoms were reported in the previous stud-
ies and were collected for this study (6-8). The patients an-
swered “yes” or “no” to each question for the presence of symp-
toms developed or aggravated at off periods during recent 2
weeks. We also compared the clinical characteristics between
M-off and NM-off groups. 
Statistical analysis
We used non-parametric Mann-Whitney U test and Pear-
sonchi-square test with the help of SPSS 12.0 (SPSS Inc., Chica-
go, IL, U.S.A.) to compare the characteristics between M-off
and NM-off groups. Spearman’s correlation test and Pearson
chi square test were used to find the correlation between
NMOS and clinical characteristics. p values of less than 0.05
were accepted as significant. 
RESULTS
Clinical spectrum and frequency of NMOS
Of 67 patients with motor fluctuations, 47 patients (70.1%,
15 males and 32 females) had both motor and non-motor
symptoms (NM-off group), and 20 patients (8 males and 12
females) had motor symptoms alone (M-off group) during off
periods. Of the 31 symptoms investigated, diffuse pain was
the most common NMS, followed by anxiety, sweating, pal-
pitation, fatigue, abdominal bloating, and dizziness. Patients
had an average of 3.5 symptoms (range 1 to 12). Autonomic
symptoms were more frequent (79.2%) than sensory and co-
gnitive/psychiatric symptoms (52.1%, each) (Table 3).
Comparison between M-off and NM-off groups
Sex, age, age of disease onset, symptom of onset, duration
of disease and treatment, interval between onset of parkinso-
nian symptoms and off symptoms, and between dopaminer-
gic treatment and onset of motor fluctuations were not signi-
ficantly different between M-off and NM-off groups. Patients
of M-off group showed more frequent off dystonia but the
difference was not significant. Other characteristics such as
The Unified Parkinson’s Disease Rating Scale (UPDRS) scores
of motor symptoms, Hoehn and Yahr stage and medication
(levodopa equivalent dose, dopamine agonist, MAOB/COMT
inhibitor, anxiolytics and antidepressant), showed no statis-
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Autonomic symptoms
Cognitive/psychiatric Sensory
symptoms symptoms
Laryngeal stridor Hot flushing  Anxiety/panic Diffuse pain
Anismus Palpitation Fatigue Neuralgic pain
Sweating Pallor Moaning/ Paresthesia/
screaming numbness
Urinary problem Drooling Depression Akathisia
Constipation Visual disorder Cognitive changes
Distal coldness Dysphagia Sexual disorder
Nausea Dyspnea Hyperactivity
Dizziness Abdominal Hallucination
bloating
Table 1. Non-motor symptoms during off period
Data are presented as mean±SD unless otherwise indicated. 
*interval between onset of parkinsonian symptoms and off symptoms;
� sum of scores of rigidity, tremor & bradykinesia.
PD, Parkinson’s disease.
Motor off  Non-motor off
Number of patients 20 47
Male:female 8:12 15:32
Age (yr)  57.6±10.6 58.5±10.1
PD symptom duration (yr) 10.1±7.1 9.0±5.2
Treatment duration (months) 81.5±55.7 84.7±49.9
Interval (months)* 49.3±37.5 52.3±38.9
Off duration (months) 32.1±28.4 32.4±28.6
Levodopa dose (mg/day) 799.1±287.3 716.5±327.8
Motor symptom score
� 9.5±4.3 10.2±4.8
Hoehn & Yahr stage 3.0±0.4 2.9±0.6
Table 2. Characteristics of Motor off group and Non-motor off
grouptical difference between the two groups (Table 2).
Influence of the clinical characteristics on NMOS
Female patients complained about sensory symptoms more
frequently (50.0% vs. 13.0%, p=0.003). However, the dura-
tion of parkinsonian symptoms and treatment in female group
were significantly shorter than those of the male group. Psy-
chiatric symptoms were more common in the younger group
(age below median 59 yr, 50.0% vs. 25.7%, p=0.040) in spite
of milder motor symptoms and HY stages. We could not find
any influence of age at disease onset, duration of disease and
treatment, severity of motor symptoms, and Hoehn and Yahr
stage on NMOS. Mean dose of levodopa showed significant
influences on NMOS. Patients taking higher doses of levodo-
pa (dose above median 750 mg/day) had significantly fewer
NMOS (1.6±1.8 vs. 3.3±3.2, p=0.024), especially in auto-
nomic (0.8±1.1 vs. 1.8±1.9, p=0.033) symptoms.
The number of autonomic symptoms that patients had at
‘off’ state was negatively correlated with dose of levodopa (r=
-0.255, p=0.038) and positively with motor symptom score
(r=0.247, p=0.047)
DISCUSSION
Management of PD has been mainly focused on the treat-
ment of motor symptoms. Dopaminergic replacement has
shown great improvement on motor dysfunctions in PD pa-
tients. In contrast to motor symptoms, NMS of PD have re-
ceived relatively little attention, despite diverse presentations
of these conditions and their impact on the quality of life.
However, some physicians have devoted significant attention
to the NMS of PD (5, 13). These efforts moved the Movement
Disorder Society to modify the existing UPDRS to include
independent subpart of NMS (14). 
NMS are very diverse and common in PD patients (1).
These symptoms can occur any time during the illness, even
before presentation of motor symptoms. Like motor symp-
toms, NMS begin to fluctuate as the illness progresses (6).
However, it is difficult to find convincing evidence that many
of NMSF are exclusively related to PD. For example, anxi-
ety, which was reported to be the most common NMSF asso-
ciated with PD, may be due to many other conditions besides
PD (7). As a result, the frequency of NMSF might be over-
estimated. Therefore, in our study, we strictly defined NMOS
as NMS developed or aggravated during motor off periods
and investigated the prevalence of NMOS to avoid the con-
tamination of non-specific subjective symptoms that might
occur independently of PD. We also administered a structured
questionnaire about a wide range of symptoms typically expe-
rienced during the motor off period. This type of question-
naire was designed to overcome the underestimation of NMS
that would result from asking a single question with an open
answer (‘Tell us about any symptom that are associated with
the off state’) (7).
The overall rate of NMOS in this study was 71.6%. Pre-
vious studies that focused on NMSF reported a wide range
of prevalence, between 17% and 100%, of NMS among PD
patients showing motor fluctuations. Hillen et al. reported
that only 17% of patients with fluctuant PD had NMSF (8).
They used a single question with an open answer and likely
underestimated the prevalence of NMS. On the other hand,
Witjas et al. reported that all patients had at least one type of
NMSF, most of which were associated with the off state (7).
This study overestimated the prevalence because they includ-
ed NMS that occurred not only during the off period, but
other periods as well. The estimated prevalence (71.6%) in
our study may not reflect all the NMS because we excluded
NMS that may occur during periods other than off state and
might be slightly underestimated. However, this approach
offers some implications for the management of NMS. Many
NMS are subjective and vague. When these symptoms occur
during off phase, we can avoid unnecessary investigation and
useless treatments by recognizing these symptoms as part of
PD. In addition, NMOS can be managed by rearrangement
of dopaminergic regimen (9). On the other hand, when NMS
that are not associated with PD occurs and is wrongly consid-
ered as symptoms of NMSF, the chance of proper management
will be missed. 
Unlike previous studies (7, 8, 15, 17), diffuse pain was the
most frequent NMOS (50%) in our study. These discrepan-
cies may be attributed to methodological differences. Our study
counted NMS occurring during off periods and suggests that
non-motor sensory symptoms are exclusive to the off period. It
Sensory symptoms- Diffuse pain 24 (50.0)
26 patients (37.8%) Neuralgic pain 3 (6.0)
Paresthesia/numbness 3 (6.0)
Akathisia 2 (4.2)
Cognitive/psychiatric Anxiety/panic 19  (39.6)
symptoms- Fatigue 13 (27.1)
26 patients (37.8%) Depression 8 (16.7)
Cognitive changes 7 (14.6)
Sexual disorders 2 (4.2)
Autonomic symptoms- Sweating 15 (31.3)
38 patients (58.3%) Palpitation 14 (29.2)
Abdominal bloating 10 (20.1)
Dizziness 9 (18.8)
Constipation 8 (16.7)
Hot flushing 7 (14.6)
Urinary problem 7 (14.6)
Nausea 5 (10.4)
Dyspnea 4 (8.3)
Drooling 2 (4.2)
Anismus 2 (4.2)
Dysphagia 1 (2.1)
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Non-motor off symptoms No. of patients (%)
Table 3. Frequency of non-motor off symptomsalso suggests that sensory symptoms, unlike most of NMS
which does not respond to dopaminergic therapy, are largely
related to dopaminergic system. This conclusion is supported
by the fact that most of sensory symptoms that occur during
the off period can be relieved by dopaminergic therapy (9, 15).
The next most common NMOS are anxiety and sweating
(39.6 & 31.3%, respectively). This result has recapitulated by
other authors (7). Akathisia, sensory dyspnea, and depressed
mood were also common symptoms in other reports (15). Dy-
sautonomic symptoms, such as palpitation, abdominal bloat-
ing, dizziness, constipation, were also prevalent (more than
15% of the patients) and these can lead to medical attention
resulting in unnecessary tests and treatments. 
Intriguingly, results of our study suggest that women pa-
tients had less severe motor symptoms, yet experienced more
frequent NMOS. Additionally, patients with younger onset
had more frequent psychiatric NMOS. Several explanations
are possible. Generally, women patients are more willing to
express their uncomfortable symptoms. More importantly,
both women and patients with younger onset have had lower
dosage of levodopa compared to men and patients with older
onset due to concerns about levodopa-induced motor com-
plications. It is not surprising that patients taking higher dos-
age of levodopa had less frequent NMS because, in our study
excluding NMS that might occur during peak-dose or bipha-
sic periods, higher levodopa dosages reduce the off time or
severity of symptom and alleviate the NMOS associated with
dopamine system. 
The pathophysiology of motor fluctuation remains unclear.
However, evidence definitely indicates that it relates to dopa-
minergic treatment (6). NMS also fluctuates as the illness pro-
gresses. These symptoms usually appear during ‘off’ periods,
but may also occur during ‘on’ or biphasic periods. The fact
that NMSF are usually in harmony with the motor fluctua-
tion in PD suggests that the dopaminergic system is involved
in the modulation of other neurotransmitters, such as sero-
tonin or norepinephrine (6, 16). These neurotrasmitters might
fluctuate along with dopamine and be involved in the patho-
physiology of NMSF, either directly or indirectly. Gunal et
al. reported that early age of disease onset, longer duration
of disease and higher dose of levodopa could be risk factors
for sensory fluctuation (17). It is conceivable that those risk
factors, well known for motor fluctuation, could also be relat-
ed to sensory fluctuation. This is because this fluctuation oc-
curred exclusively during motor ‘off’ periods in their study,
suggesting that sensory symptoms are linked to the dopamin-
ergic system. However, our results fail to find any correlation
between those factors and NMOS. Further studies will be
needed to determine whether the risk factors of motor fluctu-
ation can be applied similarly to NMSF and the pathophysi-
ology of NMSF in PD. 
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